Simcyp PBPK Simulator for COVID-19 Decision Making
Leading companies rely on the Simcyp Simulator for COVID-19 decision-making
Simcyp Simulator and COVID-19
The Simcyp PBPK Simulator is informing pivotal go/no go decisions, designing smarter trials, and targeting dose and regimen with regard to repurposed drugs for COVID-19.
About the Simcyp Simulator
Most leading pharma companies, academia and global regulators use the simulator for development and regulatory approval.
The US FDA is the largest user of the Simcyp Simulator.
The Simcyp PBPK Simulator informs decision-making relating to clinical trial design, first-in-human dosing, formulation design, virtual bioequivalence, treatment regimens for special populations, and predicting drug-drug interactions (DDIs) liability.
Simcyp’s whole body simulation approach includes genetic, physiological, and epidemiological databases, which facilitate the simulation of virtual populations using different demographics and ethnicities. The simulator also has organ-specific models, allowing it to simulate drug dispersion through the gut, different layers of the skin, the liver, the kidney, blood-brain barrier, or specific compartments in the lung.
COVID-19 Compound Files – Available Now
The population and compound files within the Simulator each have around 1,000 data items compiled and validated from literature review, laboratory data, and clinical performance. These data classes correspond to properties of (or values dependent on) a particular compound, and to data describing the demographic, physiology, genotypic and phenotypic characteristics of a specific ethnic or disease population with relevant inter-individual variability distributions.
Among the 100 or so compound files available for use in the Simulator are many that are being tested alone or in combination, for COVID-19 and other addressing other global health challenges.
That list is growing, as new therapies are identified. A partial list is as follows:
| Albendazole | DEAQ | Mefloquine |
| Albendazole sulfoxide | DEC | Piperaquine |
| Amodiaquine | DHA | Primaquine |
| Artemether | DHA from artesunate | Proguanil |
| Atovaquone | Doxycycline | Pyrimethamine |
| Azithromycin | ELQ-300 | Pyronaridine |
| Carboxyprimaquine | Hydroxychloroquine | Sulfadoxine |
| Chloroquine | Ivermectin | Tafenoquine |
| Cycloproguanil | Lumefantrine | Quinine |
詳細は下記までお問い合わせください
参照文献：
Yeo, K. et al., “Ivermectin is unlikely to be clinically efficacious against SARS-CoV-2,” Antiviral Research, April 2020
Smith, P. et al, “Dosing Will Be a Key Success Factor in Repurposing Antivirals for COVID-19,” British Journal of Clinical Pharmacology, 2020年4月17日
Yeo, et al., “Simulating the impact of disease on plasma and lung exposure of chloroquine, hydroxychloroquine and azithromycin in COVID-19 patients: application of PBPK modelling,” submitted to Clinical Pharmacology & Therapeutics, April 2020
Gaohua L, et al., ‘Development of a Multicompartment Permeability‐Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs,’ Clinical Pharmacology & Therapeutics, Oct 2015
Laurens F.M. Verscheijden, et al. ‘Chloroquine dosing recommendations for pediatric COVID‐19 supported by modeling and simulation,” Clinical Pharmacology & Therapeutics, 2020年4月22日
Shelby, M et al., ‘Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective,’ Clinical Pharmacology & Therapeutics, July, 2018
Gardner, I et al. “New tools support developing better TB drugs,” Certara blog
